Metallation of diazines XIV. First O-directed metallation of cinnolines. Metallation of 3-, 4-chloro and 3-, 4-methoxycinnolines
摘要:
The lithiation of 3-, 4-chloro and 3-, 4-methoxycinnolines was studied and good yields were obtained. When iodine was used as electrophile, 4,8-diiodo or 4,8-iodochloro compounds were prepared. A xanthone and diazepines were synthetized.
Novel processes for the coupling of alkyl, alkenyl, alkynyl, or aryl groups to the seven position of quinolines and naphthyridines is disclosed. Novel intermediates and final compounds having antibacterial activity are also described as well as the formulations for the same use.
Syntheses of sulfoxide derivatives in the benzodiazine series. Diazines. Part 37
作者:Nicolas Le Fur、Ljubica Mojovic、Alain Turck、Nelly Plé、Guy Quéguiner、Vincent Reboul、Stéphane Perrio、Patrick Metzner
DOI:10.1016/j.tet.2004.05.059
日期:2004.8
Syntheses of new sulfinylcinnolines, quinoxalines, quinazolines and phtalazines have been investigated starting from the appropriate halogenobenzodiazine derivatives. The latter were converted in one step to the corresponding sulfanyl benzodiazines which upon oxidation with m-CPBA led to the corresponding sulfoxide derivatives of benzodiazines in moderate to good yields. In parallel to this study,
Compounds of the formula I:
or a pharmaceutical salt thereof,
wherein X, Ar
1
, R1, R
2
, R
3
, R
4
, R
5
, R
6
and R
7
are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
[EN] 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR<br/>[FR] MODULATEURS ALLOSTÉRIQUES DE TYPE 3-(1H-PYRAZOL-4-YL)PYRIDINE DU RÉCEPTEUR MUSCARINIQUE M4 D'ACÉTYLCHOLINE
申请人:MERCK SHARP & DOHME
公开号:WO2019005587A1
公开(公告)日:2019-01-03
The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.